Support from readers like you keeps The Journal open.
You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.
If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.
Kayla, Sam and Sarah Bailey Fiona Bailey
Fiona Bailey
PARENTS OF CHILDREN with a rare genetic condition have called for negotiations between the HSE and a pharmaceutical company over access to a drug to be sped up.
Last month, the HSE confirmed that it would not reimburse Spinraza (also known as Nusinersen) at its current price.
The organisation said the medication would cost more than €20 million over a five-year period – €600,000 per patient for the first year and €380,000 per patient per year thereafter.
Biogen, the company which makes Spinraza, said these figures are out of date but, when asked by TheJournal.ie to elaborate, said it “cannot comment on pricing”.
Twenty-six children in Ireland who have Spinal Muscular Atrophy (SMA), a rare and life-limiting muscle-wasting condition, could benefit from Spinraza.
Fiona Bailey, whose son Sam has SMA, said it is “heartbreaking” and “frustrating” for parents to watch protracted negotiations while their children become weaker.
Twenty-five of the 28 countries in the European Union have granted access to the medication, except Ireland, the UK (bar Scotland) and Estonia.
SMA Ireland has called on the HSE to reverse its decision; and held a protest outside Leinster House on 28 February.
Negotiations, and clashes, over pricing are ongoing behind the scenes. Biogen has hit out at the process used by the National Centre for Pharmacoeconomics (NCPE) to assess the cost-effectiveness of medication.
In turn, the NCPE’s Director, Professor Michael Barry, sharply criticised the “exorbitant” prices charged by pharmaceutical companies for certain medication, such as Spinraza.
In December 2017, the NCPE did not recommend the reimbursement of Spinraza as it was not deemed “cost-effective”. Its estimated the cost at that time was €37.88 million over five years.
As well as the cost, the HSE also cited the “limitations of the current evidence on clinical effectiveness” of Spinraza when announcing its decision not to reimburse the drug last month.
‘Urgent reform needed’
Biogen has criticised the process used by the NCPE in assessing medication. A spokesperson said: “In SMA there are challenges associated with producing the type of data that the NCPE need to see when reviewing Nusinersen in a general health technology assessment process to determine cost-effectiveness.
“For example, measuring quality of life in a young paediatric population is very difficult, and yet it is a major determining factor of cost-effectiveness in the NCPE process.”
The spokesperson said other challenges “include the uncertainty around long-term health outcomes that inevitably come with a significant therapeutic advancement”.
While the data we have so far is extremely compelling, there are only so many years of data available and limited comparators, which makes determining cost-effectiveness very difficult.
“In more specialised reimbursement methodologies, such as what is now available in Scotland, these kinds of factors are considered.”
Biogen has repeatedly called on the HSE to “urgently reform the appraisal process for orphan medicines like Nusinersen – to allow a greater degree of flexibility for the assessment of such treatment options”.
‘An easy target’
When asked about Biogen’s comments, Professor Barry defended the process used by the NCPE, saying the company’s statement is “typical of what we have come to expect from the pharmaceutical industry here in Ireland”.
He told TheJournal.ie the assessment process is “an easy target for the industry” and “an excuse for not dealing with the fundamental problem of exorbitant pricing of medicines that frequently add little in terms of health outcomes”.
“The failure to reimburse these extremely high-cost drugs is not due to the assessment process, it is due to a funding issue. One of the main purposes of the assessment process is to support the HSE in its discussions and negotiations with the pharmaceutical companies.
I would argue that it is not the assessment process that should be “urgently reformed” but the unrealistic pricing strategies being practiced by the pharmaceutical industry. There is a very clear way to get drugs reimbursed in Ireland and that is to price them fairly.
Barry said we often hear the industry talk about pricing but “rarely about value”.
The reality is that many of the new expensive medicines offer little in terms of health outcomes. In many cases we would be far better off placing our scarce healthcare resources into other areas of the health service like looking after our elderly patients, investing in mental health and disabilities not to mention investing in general practice.
The National Institute for Health and Care Excellence (NICE) in the UK met again last week to discuss reimbursing Spinraza. A decision is expected next month.
Barry added that highlighting what is going on in other countries is “also of limited value”.
“I have not heard anyone discuss the Orkambi situation in England, where reimbursement is still not approved almost two years after the drug was reimbursed in Ireland.
In addition, the concept that drugs should be reimbursed in Ireland just because they are reimbursed elsewhere is a flawed argument as it does not consider value of the drug or the differences in healthcare systems across Europe, the differing abilities to pay and, crucially, the complete absence of transparency of the various ‘deals’ being done in the different countries.
Barry said the problem is “a direct result of pharma pricing strategies”, adding: “The answer is in their own hands.”
Advertisement
Last month Barry told the Sunday Business Post the HSE had already “almost exhausted” the available funding for new drugs for the whole of 2019.
‘The weakest children in Ireland’
About one in 11,000 babies are affected by SMA – a debilitating disease that causes progressive muscle weakness and loss of movement due to muscle wasting.
SMA is the number one genetic cause of death of infants and is in the same family as motor neurone disease.
The most common form of the disease is 5q SMA, which has four different types: 1, 2, 3 and 4– based on age of onset and the highest physical milestone achieved. Type 1 is the most severe form of SMA and accounts for between 50–70% of cases of childhood onset SMA. About 95% of children with Type 1 who are untreated die before the age of two.
SMA Ireland
SMA Ireland
Children who have been granted access to Spinraza, have generally responded well, with some gaining strength and motors skills and reaching milestones previously thought impossible. The medication is delivered through the lower back via a lumbar puncture.
Sam Bailey is one of the 26 children who could benefit from the drug; he has SMA Type 2. His mother Fiona is among the parents who have been campaigning for access to Spinraza. She gave an impassioned speech at the recent rally outside Leinster House.
Speaking to TheJournal.ie, Fiona said waiting for a decision while negotiations go on behind the scenes is “heartbreaking”.
“Twenty-five other countries [in the EU] granted access to Spinraza, some as long as a year ago.
“The details are up to Biogen and the NCPE to hammer out. Our lives are full with trying to contain this disease and keep out children pain-free.”
Fiona Bailey, whose son Sam has SMA, calling for access to 'miracle drug'Spinraza. She says Sam and other children with the rare muscle-wasting condition need access to Spinraza urgently. pic.twitter.com/3cEsYvDvk3
Fiona said she’d “move over [to Scotland] in the morning if Sam could get the drug” but that it isn’t available to people from other countries.
We’re part of the EU, how can we be any different? To me it’s nonsensical, our kids are not getting same treatment as kids in other countries … Our country is failing these children spectacularly.
Parents in Ireland are keeping a close eye on Spinraza negotiations in the UK. Two babies and a teenager have died since the start of the campaign there. “Is that what’s going to happen in Ireland? It’s just terrifying for parents,” Fiona said.
Sam and the other 25 kids are the most vulnerable kids in the country – they can’t do anything for themselves, they need 24-hour care.
She said families “will be back outside the gates of the Dáil” if they need to be but she hopes the situation will be resolved soon.
“It’s terrible to have to put our children through that – children in wheelchairs outside Leinster House, literally begging for their lives.”
‘It’s a miracle he’s still alive’
Sam celebrated his ninth birthday last Wednesday. Fiona said her son is “the same as any other kid” and “was delighted with himself” on the day. However, he is aware of what is going on.
Sam will not see his teenage years if he doesn’t get Spinraza, the fact he’s here today is actually a miracle.
“He was borderline Type 1 at diagnosis, those children don’t normally see their second birthday.
“One chest infection could put Sam in hospital, could put him in ICU. If he gets sick, his life hangs in the balance – he’s one of the most severe sufferers of Type 2 in the country.”
The Bailey family at Sam's ninth birthday party during the week. Fiona Bailey
Fiona Bailey
Fiona said she is obviously aware that Spinraza is an expensive drug but pointed out that so is a spell in ICU or full-time care, which would need to be provided if “God forbid, anything happened me or Paul (Sam’s father)”.
She said getting access to Spinraza would not only be life-changing for Sam but for the whole family. “Sarah and Kayla (his sisters, who are about to turn three and seven) are watching him get weaker, they’re seeking reassurances too,” she said.
“He is losing strength every single month, every single week.”
‘Very vulnerable group’
When asked about the ongoing negotiations, a spokesperson for the HSE said “it would be inappropriate to comment” beyond its recent statement until the process is complete.
In its statement last month the HSE said it “regrets” that it has to date been unable to come to an agreement with Biogen.
Sarah, Sam and Kayla Bailey at Dublin Zoo Fiona Bailey
Fiona Bailey
The HSE said when assessing Spinraza, the organisation’s Drugs Group focused on two areas: reviewing the evidence of the clinical effectiveness of drug (the benefits for patients undergoing clinical trials) and the cost-effectiveness of the drug.
“While the HSE is anxious to provide all possible support to this very vulnerable group of patients and those who care for them, the decision reached by the Leadership Team concurs with the recommendation of the Drugs Group, which is that reimbursement could not be approved at the price currently being charged by the pharmaceutical company,” the statement said.
Under the requirements of the Health (Pricing and Supply of Medical Goods) Act 2013, Biogen has 28 days from the date of notification to respond or make representations to the HSE’s proposed decision.
To embed this post, copy the code below on your site
Close
13 Comments
This is YOUR comments community. Stay civil, stay constructive, stay on topic.
Please familiarise yourself with our comments policy
here
before taking part.
Nowadays you need to spend as much time deciphering what they are looking for as you do looking at jobs. The other day I spotted a job that spent an entire paragraph trying to say that they were looking for a sales rep to manage accounts, look for new business and reach targets. What really caught me was about half way through the mindless twaddle was the line that went something like…
“You will be more of a hunter than a farmer”
One moment they are looking for a FMCG sales, rep the next they seemed to be discriminating against members of the agricultural community in favour of members of the bloodsports crowd. A bit of research later and this particular piece of business bull$hit was revealed to mean that while managing and maintaining a present customer base would be part of the job, your main focus would be seeking new business both through cross selling and new customer acquisition. Why not just say that FFS, I mean if you are a sales rep then that is your job no matter what business you are in.
Brian I like you would hate this kind of advertising speak in a job spec but the point of the whole thing might be to attract the kind of people that really buy into this kind of rhetoric and thereby putting a subliminal person spec in the advertisement. As it would infuriate me I would never consider applying for a job like that and the company is probably happy to avoid people that don’t fit their culture from applying.
The worst are the ones who, rather than list their job title and company they work for, instead go for some existential explanation of how, while working in their depressing little cubical and counting the days to retirement, they are really changing the world.
You know the ones I mean
“-Don Smith-
Transforming the way clients engage with their customers one-to-one through unique visualization of significant future milestones.”
Oh no, Don isn’t a sales rep, Don is an Accounts Executive. Linda isn’t a secretary she’s a PA, it isn’t even a Personal Assistant any more. Maybe because Personal Assistant sounds a bit medical, like they help the boss go to the toilet and dress themselves…..actually quite a lot of PAs are only just short of doing that from what I’ve heard.
People getting notions! The IT industry has to change every title, can’t be seen to be using boring old traditional commercial structures and titles, everyone is a coding rockstar or angular Dev guru. Some of the companies are almost like cults who try to absorb employees into their way of thinking and living. Ie solely in the building! Don’t go out for lunch we give you a free canteen. Think you might be too busy to get to the canteen? We’ll deliver to your desk! You are too busy aren’t you, you’d better eat at your desk. You’ve been to the canteen three days in a row, the staff know your order, they’ll deliver it to you, no worries, all part of being a valued member of our team, NOW DON’T LEAVE YOUR FU(K|NG DESK!
@bazhealy I avoid job roles with the word Rockstar or Guru. I am a Web Developer, but more recently they have branched it out to Frontend Developers and Backend Developers, so currently I’m a UI/UX Developer. Still means nothing to anyone.
Who’s, what about being a “Ninja”? I see a lot of jobs nowadays for (programming/IT) Ninja’s. Does mean 4 years in a 3rd level institution and another 15-20 in Japan learning how to silently kill your opponents with a paper clip while debugging code?
@baz. I agree about IT companies. The real cringe-worthy ones are when they tell you that you will receive other benefits that make up for your lack of monetary reward such as being allowed to come to work in jeans, T-shirts and runners and being part of the XXXXX team, get free training inhouse (once heard a company describe themselves as a “university” for providing this nontransferable “training”). They also made a big deal out of the manager having breakfast with different groups of staff every Friday. Everyone paid for their own, needless to say. That foreign company now long gone and staff back on dole.
half of them wouldn’t cut. anyone can say anything. I’m aware of people changing their titles every 6 months and they NOT have those skills, more a rough idea, i know cos i know who they are. Or the other one under skills “getting back in touch” mwuahaha. they’re the worse communicators I’ve ever come across, get back in touch alright, if theres something in it for them, not a natural trait. theres options there for connecting with people, do not add people you don’t know but many famous people will accept, cos they don’t care, then many have it locked down and rightly so. “oh i have to reach 500+, i have to”, you’d think Facebook was bad. i think a brief intro is enough and apply with the full truth by email so they can check it.
Linkedin seems to be the Facebook of the business world. People from all over the globe sending you “friend” requests just to bolster the amount of people in their “network”. Then they endorse your achievements hoping that you in turn will endorse them. It turns into a bit of a joke really because the whole thing is so fake.
I’d love to interview one of these people and pull a random name from their network list and ask them for example, what their relationship is with “Gunjar Singh” who is CEO of the Golden Dome Mobile Phone Store located on Baital Aman Jamemosjid Rd, Dhaka, Bangladesh? It’s just that Mr Singh endorsed your qualities of leadership, sales, marketing, passionate, enthusiastic, creative, team leader and so on and I was wondering how you came to meet or do business with this person seeing as how they gave you such glowing endorsements.
What’s the deal with people referring to themselves in the third person on their linked in profile? “John is a highly motivated individual with proven track record of exceeding targets” and so on.. Are you schizophrenic?
This is one site I never really got or understood. Anyone find it useful, genuinely useful? I’m self-employed so I’m assuming it’s not targeted at me? What’s the purpose of it?
It’s like Facebook except people’s profile pictures are like a collection of adult communion photos and instead of posting dinner pics people share achievements of other people talking about how we can all achieve success through mindfulness using the cloud. You can see who stalks your profile which is nice.
Don’t forget the random pictures of Leonardo Di Capri in a suit, from Wolf of Wall St, accompanied by the inspirational quote about being successful in business.
Useful to have 500+ recruiters add you to try and badger you into this “perfect” role they have. I’ve gotten recruiters who in their haste to send a stock message, have neglected to actually read your profile and have sent a job the does not in anyway match your skillset. They essentially scan for a few acronyms to tick a box.
Brendan i’m going to reach out to you in order to touch base going forward. Let’s get all our ducks in a row here and really brainstorm some blue sky thinking and see how much of our business we can move to the cloud.
LinkedIn works fine got my last 5 contracts through it.
Never accept a connection from a stranger will solve a lot of the issues people are complaining about.
It is the fact people treat it like Facebook that makes it useless to them.
‘Loss of momentum’: Target of 41,000 homes built this year looks set to be missed by 6,000
Diarmuid Pepper
6 hrs ago
2.8k
26
prescriptions
Social Prescribing: What is it all about and how can it help our health?
4 mins ago
22
0
Ceasefire violation
'Bodies and limbs on the ground' after Israeli strikes kill more than 400 people in Gaza
Updated
11 hrs ago
40.6k
Your Cookies. Your Choice.
Cookies help provide our news service while also enabling the advertising needed to fund this work.
We categorise cookies as Necessary, Performance (used to analyse the site performance) and Targeting (used to target advertising which helps us keep this service free).
We and our 157 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting Accept All enables tracking technologies to support the purposes shown under we and our partners process data to provide. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the Cookie Preferences link on the bottom of the webpage .Your choices will have effect within our Website. For more details, refer to our Privacy Policy.
We and our vendors process data for the following purposes:
Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a device. Personalised advertising and content, advertising and content measurement, audience research and services development.
Cookies Preference Centre
We process your data to deliver content or advertisements and measure the delivery of such content or advertisements to extract insights about our website. We share this information with our partners on the basis of consent. You may exercise your right to consent, based on a specific purpose below or at a partner level in the link under each purpose. Some vendors may process your data based on their legitimate interests, which does not require your consent. You cannot object to tracking technologies placed to ensure security, prevent fraud, fix errors, or deliver and present advertising and content, and precise geolocation data and active scanning of device characteristics for identification may be used to support this purpose. This exception does not apply to targeted advertising. These choices will be signaled to our vendors participating in the Transparency and Consent Framework.
Manage Consent Preferences
Necessary Cookies
Always Active
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then these services may not function properly.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not be able to monitor our performance.
Store and/or access information on a device 109 partners can use this purpose
Cookies, device or similar online identifiers (e.g. login-based identifiers, randomly assigned identifiers, network based identifiers) together with other information (e.g. browser type and information, language, screen size, supported technologies etc.) can be stored or read on your device to recognise it each time it connects to an app or to a website, for one or several of the purposes presented here.
Personalised advertising and content, advertising and content measurement, audience research and services development 141 partners can use this purpose
Use limited data to select advertising 111 partners can use this purpose
Advertising presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type or which content you are (or have been) interacting with (for example, to limit the number of times an ad is presented to you).
Create profiles for personalised advertising 83 partners can use this purpose
Information about your activity on this service (such as forms you submit, content you look at) can be stored and combined with other information about you (for example, information from your previous activity on this service and other websites or apps) or similar users. This is then used to build or improve a profile about you (that might include possible interests and personal aspects). Your profile can be used (also later) to present advertising that appears more relevant based on your possible interests by this and other entities.
Use profiles to select personalised advertising 83 partners can use this purpose
Advertising presented to you on this service can be based on your advertising profiles, which can reflect your activity on this service or other websites or apps (like the forms you submit, content you look at), possible interests and personal aspects.
Create profiles to personalise content 38 partners can use this purpose
Information about your activity on this service (for instance, forms you submit, non-advertising content you look at) can be stored and combined with other information about you (such as your previous activity on this service or other websites or apps) or similar users. This is then used to build or improve a profile about you (which might for example include possible interests and personal aspects). Your profile can be used (also later) to present content that appears more relevant based on your possible interests, such as by adapting the order in which content is shown to you, so that it is even easier for you to find content that matches your interests.
Use profiles to select personalised content 34 partners can use this purpose
Content presented to you on this service can be based on your content personalisation profiles, which can reflect your activity on this or other services (for instance, the forms you submit, content you look at), possible interests and personal aspects. This can for example be used to adapt the order in which content is shown to you, so that it is even easier for you to find (non-advertising) content that matches your interests.
Measure advertising performance 132 partners can use this purpose
Information regarding which advertising is presented to you and how you interact with it can be used to determine how well an advert has worked for you or other users and whether the goals of the advertising were reached. For instance, whether you saw an ad, whether you clicked on it, whether it led you to buy a product or visit a website, etc. This is very helpful to understand the relevance of advertising campaigns.
Measure content performance 60 partners can use this purpose
Information regarding which content is presented to you and how you interact with it can be used to determine whether the (non-advertising) content e.g. reached its intended audience and matched your interests. For instance, whether you read an article, watch a video, listen to a podcast or look at a product description, how long you spent on this service and the web pages you visit etc. This is very helpful to understand the relevance of (non-advertising) content that is shown to you.
Understand audiences through statistics or combinations of data from different sources 74 partners can use this purpose
Reports can be generated based on the combination of data sets (like user profiles, statistics, market research, analytics data) regarding your interactions and those of other users with advertising or (non-advertising) content to identify common characteristics (for instance, to determine which target audiences are more receptive to an ad campaign or to certain contents).
Develop and improve services 83 partners can use this purpose
Information about your activity on this service, such as your interaction with ads or content, can be very helpful to improve products and services and to build new products and services based on user interactions, the type of audience, etc. This specific purpose does not include the development or improvement of user profiles and identifiers.
Use limited data to select content 38 partners can use this purpose
Content presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type, or which content you are (or have been) interacting with (for example, to limit the number of times a video or an article is presented to you).
Use precise geolocation data 46 partners can use this special feature
With your acceptance, your precise location (within a radius of less than 500 metres) may be used in support of the purposes explained in this notice.
Actively scan device characteristics for identification 27 partners can use this special feature
With your acceptance, certain characteristics specific to your device might be requested and used to distinguish it from other devices (such as the installed fonts or plugins, the resolution of your screen) in support of the purposes explained in this notice.
Ensure security, prevent and detect fraud, and fix errors 90 partners can use this special purpose
Always Active
Your data can be used to monitor for and prevent unusual and possibly fraudulent activity (for example, regarding advertising, ad clicks by bots), and ensure systems and processes work properly and securely. It can also be used to correct any problems you, the publisher or the advertiser may encounter in the delivery of content and ads and in your interaction with them.
Deliver and present advertising and content 97 partners can use this special purpose
Always Active
Certain information (like an IP address or device capabilities) is used to ensure the technical compatibility of the content or advertising, and to facilitate the transmission of the content or ad to your device.
Match and combine data from other data sources 72 partners can use this feature
Always Active
Information about your activity on this service may be matched and combined with other information relating to you and originating from various sources (for instance your activity on a separate online service, your use of a loyalty card in-store, or your answers to a survey), in support of the purposes explained in this notice.
Link different devices 53 partners can use this feature
Always Active
In support of the purposes explained in this notice, your device might be considered as likely linked to other devices that belong to you or your household (for instance because you are logged in to the same service on both your phone and your computer, or because you may use the same Internet connection on both devices).
Identify devices based on information transmitted automatically 86 partners can use this feature
Always Active
Your device might be distinguished from other devices based on information it automatically sends when accessing the Internet (for instance, the IP address of your Internet connection or the type of browser you are using) in support of the purposes exposed in this notice.
Save and communicate privacy choices 68 partners can use this special purpose
Always Active
The choices you make regarding the purposes and entities listed in this notice are saved and made available to those entities in the form of digital signals (such as a string of characters). This is necessary in order to enable both this service and those entities to respect such choices.
have your say